December 20, 2014 4:43 PM ET

Healthcare Equipment and Supplies

Company Overview of NeuroPace, Inc.

Company Overview

NeuroPace, Inc. designs, develops, manufactures, and markets implantable devices for the treatment of neurological disorders by responsive brain stimulation. The company offers RNS System, a device for the treatment of medically refractory partial epilepsy. Its RNS System includes implantable components comprising RNS neurostimulator, a programmable, battery powered, and microprocessor-controlled device that delivers a short train of electrical pulses to the brain through implanted leads; and depth leads and cortical strip leads. The company’s RNS system also includes external products, such as programmer, a laptop computer that communicates with an implanted RNS neurostimulator enabling the...

455 North Bernardo Avenue

Mountain View, CA 94043

United States

Founded in 1997

Phone:

650-237-2700

Fax:

650-237-2701

Key Executives for NeuroPace, Inc.

Chief Executive Officer
Age: 72
Chief Financial Officer and Vice President of Finance & Administration
Chief Medical Officer
Vice President of Quality Assurance and Manufacturing Operations
Vice President of Regulatory Affairs
Compensation as of Fiscal Year 2014.

NeuroPace, Inc. Key Developments

NeuroPace, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 09:00 AM

NeuroPace, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 09:00 AM. Venue: The Palace Hotel, San Francisco, CA 94105, United States. Speakers: Martha J. Morrell, Chief Medical Officer.

NeuroPace, Inc. Announces Partnership with the Defense Advanced Research Projects Agency

NeuroPace, Inc. announced its partnership with the Defense Advanced Research Projects Agency (DARPA) Restoring Active Memory (RAM) teams at the University of Pennsylvania and the University of California, Los Angeles (UCLA) to develop new treatments for memory deficits using neurostimulation. The RNS(R) System is the world's only commercially available implantable closed-loop responsive neurostimulator system. NeuroPace received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for the RNS System in November 2013. It is approved as a treatment for adults with partial onset seizures with one or two seizure onset zones whose seizures have not been controlled with two or more antiepileptic drugs. Through the DARPA RAM research, NeuroPace and other collaborators will gain fundamental knowledge regarding the restoration of memory. The company believes this research may expand the clinical applications of the RNS System beyond the treatment of epilepsy, as well as provide the understanding necessary to inform the development of future devices that expand the capabilities of responsive neurostimulation. This collaborative effort will advance the field of brain research and closed-loop neurostimulation applications.

FDA Grants Premarket Approval for the NeuroPace, Inc.'s RNS System to Treat Medically Refractory Epilepsy

NeuroPace, Inc. announced that the U.S. Food and Drug Administration has granted premarket approval for the NeuroPace(R) RNS(R) System, a treatment for adults with partial onset seizures that have not been controlled with two or more antiepileptic drugs. The RNS System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to detect abnormal electrical activity in the brain and respond by delivering imperceptible levels of electrical stimulation to normalize brain activity before an individual experiences seizures. The RNS(R) System has been granted premarket approval (PMA) from the FDA for the treatment of adults with partial onset seizures that have not been controlled with two or more antiepileptic drugs. The RNS System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to detect abnormal electrical activity in the brain and respond by delivering imperceptible levels of electrical stimulation to normalize brain activity before an individual experiences seizures. The RNS System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures who have undergone diagnostic testing that localized no more than two epileptogenic foci, are refractory to two or more antiepileptic medications, and currently have frequent and disabling seizures (motor partial seizures, complex partial seizures and/or secondarily generalized seizures). The RNS System has demonstrated safety and effectiveness in patients who average three or more disabling seizures per month over the three most recent months (with no month with fewer than two seizures), and has not been evaluated in patients with less frequent seizures. It is estimated that approximately 400,000 people in the U.S. meet these criteria and may benefit from treatment with the RNS System. The RNS System has been evaluated in three clinical trials, including a prospective, randomized, double-blinded, sham stimulation controlled pivotal study. The pivotal study primary effectiveness endpoint was met by demonstrating a 37.9% reduction in seizure frequency in patients treated with responsive stimulation compared to a 17.3% reduction in patients who were implanted with the device but were not receiving responsive stimulation during a three month blinded period. The difference is statistically significant (p=0.012). For those subjects who reached two years post-implant, 55% of the subjects experienced a 50% or greater reduction in seizures. The pivotal trial primary safety endpoint was met by demonstrating a serious adverse event rate for the first 4 and 12 weeks post-implant comparable to similar procedures. There was no difference between the active and sham stimulation groups in the rate of adverse events, including depression, memory impairment and anxiety. There were no serious unanticipated device related adverse events reported in any of the clinical trials. Although there can be no assurances that additional long-term data will not reveal new adverse information presently unknown to NeuroPace, two year data shows no increase or worsening of adverse events. A total of 256 patients have been implanted with the RNS System. At this time, some patients have been treated with the RNS System for over eight years, and more than 1,200 patient years of experience with responsive neurostimulation have been accumulated to date.

Similar Private Companies By Industry

Company Name Region
Myomo, Inc. United States
Pal Health Technologies, Inc. United States
RhinoSystems, Inc. United States
IQuum, Inc. United States
Trident Labs, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NeuroPace, Inc., please visit www.neuropace.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.